Bipolar II Disorder Clinical Trial
Official title:
Hypomania, Amphetamine, and Preferences for Sweets
Young adults who exhibit "bipolar phenotype" (BPP), defined as occasional episodes of mood elevation and heightened activity, are at risk for several psychiatric disorders, including problem use of drugs and alcohol. Mood elevation has been linked to higher alcohol consumption and alcohol use disorders. Individuals with BPP show elevated lifetime prevalence of alcohol use disorders (between 39%-61%), figures that exceed those reported in both major depression and schizophrenia. Recently, the investigators demonstrated in a controlled laboratory study that individuals with BPP (but not meeting criteria for full Bipolar I Disorder), report dampened responses to a single dose of alcohol, compared to placebo. In the current study, the investigators seek to extend these findings to determine if young adults reporting BPP, based on a questionnaire, will exhibit reduced responses to other rewarding stimuli, such as d-amphetamine and sweet tastes. The investigators hypothesize that the BPP individuals will exhibit dampened subjective responses to stimulant and sweet taste rewards compared to healthy controls.
This study will extend the understanding of risk factors for drug or alcohol misuse, or other reward-related behaviors. The investigators previously showed that individuals who report occasional feelings of high energy and excitability experience less effect from a single dose of alcohol, compared to people who have not experienced these effects. Now the investigators wish to determine if this dampened response also occurs with other rewards, namely feelings of wellbeing after a dose of amphetamine, or liking of a sweet solution. Individuals who exhibit the BPP (i.e., periods of excitability) also are more likely to develop alcohol problems, substance misuse, and weight gain and obesity. Therefore, the investigators will test the working hypothesis that young adults who report having these experiences, based on a questionnaire measure (i.e., BPP individuals) will show dampened subjective responses to both single oral doses of amphetamine or sweet palatable tastes. The investigators will also obtain objective measures (e.g. Respiratory Sinus Arrhythmia and heart rate) to amphetamine and sweet taste, to establish whether the dampened subjective response extends to physiological indices as well. This study will extend the previous literature regarding the blunted effects of alcohol in BPP individuals and will suggest possible mechanisms that promote broader addictive behaviors in individuals with mood disturbance. Importantly, the investigators are proposing to test individuals at a relatively young age, 18-19 years. This is important to identify a risk factor, that is thought to pre-date use of drugs. In older participants, it would be difficult to separate the role of the pre-existing trait from the effect of habitual drug or alcohol use that escalates markedly after age 20. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Recruiting |
NCT05340686 -
Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression
|
N/A | |
Completed |
NCT00761761 -
Sensoril(Ashwaganhda)for Bipolar Disorder
|
Phase 3 | |
Active, not recruiting |
NCT04561622 -
Emotional Proactive Processing in Bipolar Disorder
|
||
Completed |
NCT03334721 -
Gabapentin for Bipolar & Cannabis Use Disorders
|
Phase 2 | |
Active, not recruiting |
NCT05658510 -
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
|
Phase 3 | |
Recruiting |
NCT06184581 -
Lithium Versus Lamotrigine in Bipolar Disorder, Type II
|
Phase 4 | |
Active, not recruiting |
NCT03484494 -
Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression
|
N/A | |
Recruiting |
NCT05400785 -
Efficacy of the Mobile Application for Prediction and Prevention of Mood Episode Recurrence Based on Machine Learning
|
N/A | |
Completed |
NCT05340504 -
Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder
|
Phase 2 | |
Active, not recruiting |
NCT05249309 -
Naturalistic Study of Ketamine in the Treatment of Depression
|
||
Recruiting |
NCT04211428 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder
|
||
Completed |
NCT03822416 -
Treating Smokers With Mental Illness
|
Phase 2 | |
Completed |
NCT01588457 -
Sequential Multiple Assignment Treatment for Bipolar Disorder
|
Phase 4 | |
Completed |
NCT03156504 -
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
|
Phase 4 | |
Recruiting |
NCT05004896 -
Ketamine for Treatment-Resistant Bipolar Disorder
|
Phase 2 | |
Terminated |
NCT02491307 -
Ginger.io Behavioral Health Study
|
N/A | |
Recruiting |
NCT05427123 -
Children's Bipolar Network Treatment Trial I
|
||
Not yet recruiting |
NCT05705063 -
Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness
|
N/A | |
Recruiting |
NCT05065294 -
Psilocybin Therapy for Depression in Bipolar II Disorder
|
Phase 2 |